Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bayer
University of California, Irvine
ViroMissile, Inc.
Essen Biotech
MacroGenics
Perspective Therapeutics
Ocellaris Pharma, Inc.
Var2 Pharmaceuticals
M.D. Anderson Cancer Center
Mayo Clinic
Tanabe Pharma America, Inc.
Blueprint Medicines Corporation
HiFiBiO Therapeutics
National Institutes of Health Clinical Center (CC)
Actym Therapeutics, Inc.
Washington University School of Medicine
3B Pharmaceuticals GmbH
GONGCHU Biotechnology Co., Ltd
Lantheus Medical Imaging
Jonsson Comprehensive Cancer Center
University of Pittsburgh
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
University of California, Irvine
Cancer Research UK
Hutchmed
Chinese University of Hong Kong
Stanford University
Mayo Clinic
Stanford University
Cybrexa Therapeutics
Stanford University
TopAlliance Biosciences
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai PerHum Therapeutics Co., Ltd.
Peking University
Taiho Pharmaceutical Co., Ltd.
European Organisation for Research and Treatment of Cancer - EORTC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Xencor, Inc.
Stanford University
Second Affiliated Hospital of Guangzhou Medical University
TransThera Sciences (Nanjing), Inc.
DNAtrix, Inc.
BioEclipse Therapeutics
Celon Pharma SA
Adaptimmune
Ipsen
pharmaand GmbH